公开(公告)号：US20240082218A1

公开(公告)日：2024-03-14

申请号：US18267735

申请日：2021-12-20

Applicant: NOVARTIS AG

Inventor： Vasileios ASKOXYLAKIS ,  Saskia Maria BRACHMANN ,  Simona COTESTA ,  Xiaoming CUI ,  Jeffrey ENGELMAN ,  Anna FARAGO ,  Marc GERSPACHER ,  Diana GRAUS PORTA ,  Catherine LEBLANC ,  Edwige Liliane Jeanne LORTHIOIS ,  Bo LIU ,  Rainer MACHAUER ,  Robert MAH ,  Christophe MURA ,  Pascal RIGOLLIER ,  Nadine SCHNEIDER ,  Stefan STUTZ ,  Andrea Helga Emmi VAUPEL ,  Nicolas WARIN ,  Andreas WEISS ,  Rainer WILCKEN ,  Padmaja YERRAMILLI-RAO

IPC: A61K31/416 ,  A61K9/00 ,  A61K31/497 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K31/416 ,  A61K9/0053 ,  A61K31/497 ,  A61K39/3955 ,  A61P35/00

Abstract: It relates to a pharmaceutical combination comprising a KRAS G12C inhibitor, in particular 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro [3.3] heptan-2-yl} prop-2-en-1-one (Compound A) and one or more therapeutically active agents selected from a SHP2 inhibitor (e.g. TNO155) and a PD-1 inhibitor, pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of a cancer or a tumor, in particular wherein the cancer or tumor is KRAS G12C mutated.